Parkinson's Disease Trial, Recruiting NCT07284342 Sponsor: AbbVie Condition: Parkinson's Disease
Back to Parkinsons Disease

Parkinson's Disease Trial, Recruiting

NCT07284342
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be 18 years old or older and have been diagnosed with advanced Parkinson's disease that responds to a medication called levodopa
  • Your doctor must have already decided to prescribe you a specific medication called foslevodopa/foscarbidopa given under the skin as an infusion, as part of your normal care — this decision must be made before you are asked to join the study
  • You must score 24 or higher on a standard memory and thinking test (called the MMSE), showing you are able to follow the study procedures
  • Your Parkinson's disease must involve significant problems with movement, such as unpredictable "on/off" periods, uncontrolled movements, or involuntary movements, after other Parkinson's medications have not worked well enough
  • If you have moderate to severe sleep apnea (a condition where breathing repeatedly stops during sleep), you may still be eligible if you are successfully using a CPAP machine (at least 4 hours per night, at least 70% of nights in the past month) or a special mouth device, and your sleep apnea is now well controlled (confirm with trial site)

Who may not be able to join:

  • You cannot join if there is a medical reason why the foslevodopa/foscarbidopa infusion medication is not safe for you to take, based on the official prescribing guidelines
  • You cannot join if you are currently taking part in another clinical trial that involves a treatment or medical procedure being tested on participants

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: ABBVIE INC., AbbVie

Phone: +34913840910

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
17 November 2025
Est. completion
1 January 2027

Where this trial is recruiting

🇪🇸 Spain

Primary endpoints

Change from Baseline on Parkinson's Disease (PD)-related sleep disturbances in Advance Parkinson's Disease (aPD) Participants, as assessed by the Parkinson's Disease Sleep Scale - 2 (PDSS-2)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov